SLC66A2

Across TCGA pan-cancer cohorts, SLC66A2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SLC66A2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLC66A2 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC66A2 is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, COAD, and LUAD are the cancer types where SLC66A2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC66A2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.411	<.001	11	view →
COAD	Female	II,III,IV	−0.760	<.001	11	view →
LUAD	Male	All	−0.650	<.001	9	view →
KICH	All	III,IV	−1.165	<.001	8	view →
KIRP	All	III,IV	−0.549	<.001	8	view →
KIRC	All	III,IV	+0.383	<.001	8	view →
BRCA	All	II,III,IV	−0.660	<.001	6	view →
STAD	All	All	+0.492	.007	6	view →
CHOL	All	All	−1.397	<.001	5	view →
BLCA	All	All	−0.430	.009	5	view →
LUSC	Male	All	−0.349	.003	4	view →
READ	Female	All	−0.821	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SLC66A2–THCA

Open the THCA breakdown →